At least $440 million in new support for public-private partnerships was allocated last month globally. Almost $230 million of that amount is earmarked for the NIH's Accelerating Medicines Partnership1 (see "Selected public-private partnerships for February 2014").
Accelerating Medicines Partnership members will collaborate on projects to identify and validate disease targets in Alzheimer's disease (AD), type 2 diabetes, rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). Over the public-private partnership's 5-year run, the NIH will provide $118.9 million in funding, and industry partners will provide the remaining $110.6 million in the form of funding and in-kind contributions.
The second-largest public-private partnership announced in February was the European Gram-Negative Antibacterial Engine (ENABLE) project, which is getting $116 million over 6 years and is focused on developing antibacterial compounds. In third place was the ARTERIA project, which has received C$49.2 million ($44.6 million) and is focused on cardiovascular disease.
Last month, the Innovative Medicines Initiative (IMI) launched the third project under its New Drugs 4 Bad Bugs (ND4BB) initiative. The ENABLE project aims to build and manage a discovery platform for testing and optimizing early discovery-stage molecules for drug-resistant, Gram-negative bacterial infections.
The seven candidates already